NYGC’s Clinical Laboratory provides an FDA-approved in vitro diagnostic test intended for the detection of 7 common somatic mutations in exon 2 codon 12 and 13 of the KRAS oncogene. The 7 detected mutations comprise >97% of all reported KRAS mutations in colorectal cancer patients. The results of this KRAS test are intended to aid the clinician in identifying colorectal cancer patients who may not benefit from anti-epidermal growth factor receptor (EGFR) therapy, such as panitumumab or cetuximab. If a person’s tumor is negative for the most common KRAS mutation, tests for other less common mutations not detected by the current test may be used to help predict therapeutic responses.
NYGC’s Clinical Laboratory returns results within 5-7 days. A report will be provided indicating if the test detects the specified variant(s).
A physician can order the test using NYGC’s test requisition form. This test requires FFPE tissue sections on slides. Samples should be shipped to NYGC overnight via FedEx. A courier service may also be feasible.